# Korsana Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/korsana-biosciences

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.korsana.com
- Total disclosed funding: $175M
- Latest round: Series A (Feb 28, 2025)
- Investors on record: 8

## About

Korsana Biosciences is a US-based biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly Alzheimer's disease, leveraging advanced delivery technologies to enhance treatment efficacy.Founded in 2024, Korsana Biosciences operates from Waltham, US. The company specializes in developing therapeutics for neurodegenerative disorders. The founder has previously established other ventures, though specific details are not disclosed. Korsana has successfully completed 2 deals, with its most recent funding round being the Series A, which raised USD 150.00 mn on February 28, 2025, with participation from investors including Foresite Capital, JP Morgan Life Sciences Private Capital, and others.Korsana Biosciences is focused on developing innovative therapeutics aimed at addressing neurodegenerative diseases, with a primary emphasis on Alzheimer's disease. Their core product, KRSA-028, is a next-generation shuttled monoclonal antibody specifically designed to target amyloid beta, a protein implicated in the pathogenesis of Alzheimer's. This therapeutic is delivered using Korsana's proprietary Therapeutic Targeting (THETA™) platform, which enhances the delivery of large molecules across the blood-brain barrier, thereby improving central nervous system (CNS) exposure. The end users of these products include patients suffering from Alzheimer's, along with caregivers and healthcare providers who are seeking effective treatment options. The company primarily targets markets in North America and Europe, where the burden of neurodegenerative diseases is most pronounced.Korsana Biosciences generates revenue through strategic partnerships and collaborations in the biotechnology sector. The company collaborates with Paragon Therapeutics to leverage their THETA™ platform in a manner that enhances the efficacy of their investigational therapies. Transactions typically involve licensing agreements and milestone payments contingent upon the achievement of specific clinical development goals. The financial structure may also include upfront payments associated with partnerships, along with ongoing royalties from product sales once they receive regulatory approval. The flagship product, KRSA-028, represents a significant focus for the company as it seeks to advance to market and provide solutions for Alzheimer’s disease, creating a potential revenue stream based on successful therapeutic outcomes.In September 2025, Korsana Biosciences raised USD 150.00 mn in Series A funding, co-led by TCG Crossover Management and Wellington Management, with participation from several other investors. The company plans to utilize the funding to advance its lead Alzheimer’s disease program through clinical development and support additional therapies for neurodegenerative diseases to achieve key milestones. This financial backing is intended to facilitate the development of upcoming products targeting various neurodegenerative conditions and to explore expansion into additional markets in North America and Europe.

## Funding rounds

- Series A, Feb 28, 2025, $150M — Wellington Management, Sanofi Ventures, Foresite Capital, Janus Henderson Investors, TCG Crossover Management, JP Morgan Life Sciences Private Capital
- Seed, Jun 30, 2024, $25M — Venrock, Fairmount Funds Management

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Seed
- Fairmount Funds Management — Seed
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A
- Janus Henderson Investors — Series A
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series A
- JP Morgan Life Sciences Private Capital (https://capitalatlas.ai/funds/jp-morgan-life-sciences-private-capital) — Series A